Clinical trials: Hepatic Decompensation
Hepatocellular Carcinoma
MONTEROSA - Italian Multicenter Observational Study to Evaluate Time to Clinical Hepatic Decompensation, Quality of Life, Effectiveness, and Safety of Tremelimumab Plus Durvalumab in Patients With Advanced or Unresectable Hepatocellular Carcinoma Who Have Received no Prior Systemic Treatment.
Italian multicenter observational study to evaluate time to clinical hepatic decompensation, quality of life, effectiveness, and safety of tremelimumab plus durvalumab in patients with advanced or unresectable hepatocellular…
- Trial name
- MONTEROSA (NCT07607769)
- Testing
- STRIDE
- Where
- 24 sites in Italy
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Hepatitis C
Follow-up Study of Patients Who Experienced Thromboembolic Events in the ENABLE Studies
The objective of this observational study is to characterize long-term (5 years post event) clinical outcomes in patients who experienced a thromboembolic event (TEE) during participation in the GSK ENABLE clinical trials.
- Trial name
- NCT01715779
- Testing
- Eltrombopag
- Volunteers
- 22 people
- Sponsor
- Novartis
Metabolic Dysfunction-associated Steatotic Liver Disease
Digital Pathology and AI for Liver Outcomes in MASLD
The aim of this multi-center, retrospective epidemiologic study is to confirm the prognostic performance of the Digital Pathology (DP) FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS), derived from standard digital…
- Trial name
- DPAILO-1 (NCT06344364)
- Testing
- Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
- Where
- 3 sites in Hong Kong, Spain
- Volunteers
- 1,241 people
- Sponsor
- PharmaNest, Inc
Hepatitis C, Cirrhosis
Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation
This study will evaluate the antiviral efficacy of combination therapy with sofosbuvir (SOF) plus ribavirin (RBV) for 48 weeks in adults with compensated and decompensated chronic hepatitis C virus (HCV) infection.
- Conditions
- Hepatitis C, Cirrhosis, Portal Hypertension, With or Without Liver Decompensation
- Trial name
- NCT01687257
- Testing
- SOF, RBV
- Where
- 9 sites in United States, Australia and 3 more
- Volunteers
- 50 people
- Sponsor
- Gilead Sciences
Liver Decompensation, Hepatocellular Carcinoma
The Second Multicenter Hemophilia Cohort Study
The Second Multicenter Hemophilia Cohort Study (MHCS-II) will evaluate and prospectively follow approximately 4500 persons with hemophilia who were exposed to hepatitis C virus (HCV).
- Conditions
- Liver Decompensation, Hepatocellular Carcinoma, Non-Hodgkin Lymphoma
- Trial name
- NCT00341705
- Where
- 48 sites in United States, Brazil and 6 more
- Volunteers
- 2,565 people
- Sponsor
- National Cancer Institute (NCI)
Liver Failure, Acute on Chronic
Chinese CLIF-C Acute-on-Chronic Liver Disease and Liver Failure Study
Acute on chronic liver failure (ACLF) is a distinct entity encompassing the acute deterioration of liver function, culminating in multiple organs failure and high short-term mortality.
- Trial name
- Ch-CANONIC (NCT02457637)
- Testing
- Standary therapy
- Where
- 16 sites in China
- Volunteers
- 2,600 people
- Sponsor
- Hai Li
Decompensated Cirrhosis, Cirrhotic Cardiomyopathy
Carvedilol + Simvastatin vs. Carvedilol Alone for Cirrhosis and Cirrhotic Cardiomyopathy and Impact on Hepatic Decompensation and Survival
Cirrhosis and portal hypertension are associated with a hyperdynamic circulation and decompensation events, including development of ascites, variceal bleeding, acute kidney injury, and susceptibility to infections.
- Conditions
- Decompensated Cirrhosis, Cirrhotic Cardiomyopathy, Cirrhosis, Liver, Left Ventricular Diastolic Dysfunction
- Trial name
- CIRROSTAT (NCT06431919)
- Testing
- Simvastatin 20mg, Carvedilol 3.125 mg
- Where
- India
- Volunteers
- 260 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Acute-On-Chronic Liver Failure, Ascites
Efficacy, Safety and Tolerability of VS-01 in Adult Patients With Acute-on-Chronic Liver Failure and Ascites (UNVEIL-IT)®
A Phase 2, multi-center, randomized, controlled, open-label study to evaluate the effects of the intraperitoneal, liposomal formulation VS-01 in patients with an acute episode of hepatic and/or extrahepatic organ dysfunctions and…
- Trial name
- NCT05900050
- Testing
- VS-01 on top of SOC, SOC (Control Group)
- Where
- 26 sites in United States, Belgium and 5 more
- Volunteers
- 15 people
- Sponsor
- Genfit
Cirrhosis
"Anticipant"-TIPS After a First Portal-hypertension-related Complication in Cirrhosis
Further decompensation (FD) in cirrhosis represents a prognostic stage associated with an even higher mortality than that associated with the first decompensation.
- Trial name
- Ant-TIPS (NCT07889726)
- Testing
- TIPS, Standard of Care (SOC)
- Where
- 8 sites in France
- Volunteers
- 266 people
- Sponsor
- University Hospital, Toulouse
Portal Hypertension, Hepatic Decompensation
Non-selective Beta-blocker in Compensated Advanced Chronic Liver Disease
The goal of this randomised controlled trial is to evaluate the effect of carvedilol (a non-selective beta-blocker) in patients with compensated advanced chronic liver disease under clinically significant portal hypertension or…
- Conditions
- Portal Hypertension, Hepatic Decompensation, Advanced Chronic Liver Disease
- Trial name
- BB_cACLD (NCT06449339)
- Testing
- Carvedilol
- Where
- Hong Kong
- Volunteers
- 474 people
- Sponsor
- Chinese University of Hong Kong